{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:08:13Z","timestamp":1784135293224,"version":"3.55.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.thromres.2026.109746","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:58:10Z","timestamp":1781135890000},"page":"109746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Coagulopathy in acute promyelocytic leukaemia: Can we better predict and prevent catastrophic bleeding?"],"prefix":"10.1016","volume":"263","author":[{"given":"Dawn","family":"Swan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Falanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Gangaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jecko","family":"Thachil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.thromres.2026.109746_bb0005","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1002\/cncr.27623","article-title":"Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008","volume":"118","author":"Chen","year":"2012","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.thromres.2026.109746_bb0010","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1080\/10428194.2019.1613540","article-title":"Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all","volume":"60","author":"Stahl","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"8010","key":"10.1016\/j.thromres.2026.109746_bb0015","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0140-6736(77)91415-5","article-title":"15\/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia","volume":"1","author":"Rowley","year":"1977","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.thromres.2026.109746_bb0020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0092-8674(93)80044-F","article-title":"The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells","volume":"74","author":"Grignani","year":"1993","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.thromres.2026.109746_bb0025","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12885-023-10612-z","article-title":"Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021","volume":"23","author":"Gill","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.thromres.2026.109746_bb0030","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fonc.2022.1062524","article-title":"The treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions","volume":"12","author":"Iyer","year":"2023","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.thromres.2026.109746_bb0035","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7326\/0003-4819-117-4-292","article-title":"The \u201cretinoic acid syndrome\u201d in acute promyelocytic leukemia","volume":"117","author":"Frankel","year":"1992","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.thromres.2026.109746_bb0040","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/leu.2017.71","article-title":"Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997\u20132013","volume":"31","author":"Lehmann","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.thromres.2026.109746_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102499","article-title":"Hemorrhage in acute promyelocytic leukemia-fibrinolysis in focus","volume":"8","author":"Sabljic","year":"2024","journal-title":"Res Pract Thromb Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2026.109746_bb0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.thromres.2004.11.001","article-title":"Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients","volume":"116","author":"Dally","year":"2005","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.thromres.2026.109746_bb0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1600-0609.2006.00803.x","article-title":"Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome","volume":"78","author":"Yanada","year":"2007","journal-title":"Eur. J. Haematol."},{"issue":"7","key":"10.1016\/j.thromres.2026.109746_bb0060","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood-2007-07-100669","article-title":"Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin","volume":"111","author":"de la Serna","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.thromres.2026.109746_bb0065","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2011.78","article-title":"Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry","volume":"25","author":"Lehmann","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.thromres.2026.109746_bb0070","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3324\/haematol.2011.046490","article-title":"Treatment advances have not improved the early death rate in acute promyelocytic leukemia","volume":"97","author":"McClellan","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.thromres.2026.109746_bb0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1600-0609.2011.01747.x","article-title":"Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia","volume":"88","author":"Chang","year":"2012","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2026.109746_bb0080","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-013-0478-y","article-title":"International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation \u2265 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia","volume":"30","author":"Mitrovic","year":"2013","journal-title":"Med. Oncol."},{"issue":"13","key":"10.1016\/j.thromres.2026.109746_bb0085","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1182\/blood-2016-10-747170","article-title":"Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era","volume":"129","author":"Mantha","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2026.109746_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2018.11.004","article-title":"Real-life outcomes on acute promyelocytic leukemia in Brazil \u2013 early deaths are still a problem","volume":"19","author":"Silva","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.thromres.2026.109746_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2019.102351","article-title":"Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone","volume":"79","author":"Hou","year":"2019","journal-title":"Blood Cells Mol. Dis."},{"issue":"10","key":"10.1016\/j.thromres.2026.109746_bb0100","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1080\/10428194.2019.1581187","article-title":"Predictors of early hemorrhage in acute promyelocytic leukemia","volume":"60","author":"Naymagon","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.thromres.2026.109746_bb0105","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s00277-020-04245-6","article-title":"Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia","volume":"99","author":"Minamiguchi","year":"2020","journal-title":"Ann. Hematol."},{"issue":"5","key":"10.1016\/j.thromres.2026.109746_bb0110","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/09537104.2020.1799969","article-title":"Investigation of fibrinogen in early bleeding of patients with newly diagnosed acute promyelocytic leukemia","volume":"32","author":"Chu","year":"2021","journal-title":"Platelets"},{"key":"10.1016\/j.thromres.2026.109746_bb0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.thromres.2021.12.020","article-title":"Predictive factors for differentiating thrombohemorrhagic disorders in high-risk acute promyelocytic leukemia","volume":"210","author":"Xiao","year":"2022","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.thromres.2026.109746_bb0120","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00277-023-05122-8","article-title":"Value of the FDP\/FIB ratio in predicting early severe bleeding events in patients with newly diagnosed acute promyelocytic leukemia","volume":"102","author":"Li","year":"2023","journal-title":"Ann. Hematol."},{"issue":"13","key":"10.1016\/j.thromres.2026.109746_bb0125","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-<em>trans<\/em> retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.thromres.2026.109746_bb0130","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(18)30295-X","article-title":"Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.thromres.2026.109746_bb0135","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/bloodadvances.2024014999","article-title":"Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly diagnosed patients: impact and outcome","volume":"9","author":"Gill","year":"2025","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.thromres.2026.109746_bb0140","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1038\/leu.2014.240","article-title":"Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients","volume":"28","author":"Rahm\u00e9","year":"2014","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.thromres.2026.109746_bb0145","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood.V124.21.3669.3669","article-title":"Evaluation of ISTH DIC score to predict significant bleeding and thrombosis events in pediatric acute promyelocytic leukemia; a report from the Children\u2019s Oncology Group AAML0631 trial","volume":"124","author":"Kutny","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2026.109746_bb0155","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s13054-025-05743-7","article-title":"Early mortality in patients with acute promyelocytic leukemia: a systematic review and meta-analysis","volume":"29","author":"Chean","year":"2025","journal-title":"Crit. Care"},{"issue":"1","key":"10.1016\/j.thromres.2026.109746_bb0160","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2011.08922.x","article-title":"The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia","volume":"156","author":"Breen","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2026.109746_bb0165","doi-asserted-by":"crossref","first-page":"19987","DOI":"10.1038\/s41598-024-71082-2","article-title":"Analysis of early death in critically ill patients with acute promyelocytic leukaemia in the HICU","volume":"14","author":"Li","year":"2024","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.thromres.2026.109746_bb0170","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1073\/pnas.0915006107","article-title":"PML\/RARalpha fusion protein transactivates the tissue factor promoter through a GAGC-containing element without direct DNA association","volume":"107","author":"Yan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.thromres.2026.109746_bb0175","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/0049-3848(88)90349-0","article-title":"Levels of thrombin-antithrombin III complex in plasma in cases of acute promyelocytic leukemia","volume":"50","author":"Asakura","year":"1988","journal-title":"Thromb. Res."},{"issue":"10","key":"10.1016\/j.thromres.2026.109746_bb0180","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/1097-0142(19821115)50:10<2106::AID-CNCR2820501022>3.0.CO;2-D","article-title":"Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin","volume":"50","author":"Sandler","year":"1982","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.thromres.2026.109746_bb0185","first-page":"2","article-title":"Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment","volume":"7","author":"Dombret","year":"1993","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.thromres.2026.109746_bb0190","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.1988.tb02432.x","article-title":"Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia","volume":"70","author":"Avvisati","year":"1988","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.thromres.2026.109746_bb0195","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1080\/10245332.2018.1470069","article-title":"Characteristics of fibrinolytic disorders in acute promyelocytic leukemia","volume":"23","author":"Wang","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.thromres.2026.109746_bb0200","doi-asserted-by":"crossref","first-page":"d341","DOI":"10.2741\/kim","article-title":"Annexin II: a plasminogen-plasminogen activator co-receptor","volume":"7","author":"Kim","year":"2002","journal-title":"Front. Biosci."},{"issue":"13","key":"10.1016\/j.thromres.2026.109746_bb0205","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJM199904013401303","article-title":"Annexin II and bleeding in acute promyelocytic leukemia","volume":"340","author":"Menell","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.thromres.2026.109746_bb0210","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.leukres.2010.11.008","article-title":"The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia","volume":"35","author":"Liu","year":"2011","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.thromres.2026.109746_bb0215","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1538-7933.2004.00593.x","article-title":"Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin","volume":"2","author":"Kwaan","year":"2004","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2026.109746_bb0220","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.beha.2008.12.007","article-title":"The coagulopathy of acute promyelocytic leukaemia revisited","volume":"22","author":"Stein","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"4","key":"10.1016\/j.thromres.2026.109746_bb0225","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/hon.867","article-title":"Acute promyelocytic leukaemia and acquired \u03b1-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients","volume":"26","author":"Wassenaar","year":"2008","journal-title":"Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.thromres.2026.109746_bb0230","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1182\/blood.V77.9.1949.1949","article-title":"The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia","volume":"77","author":"Sakata","year":"1991","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.thromres.2026.109746_bb0235","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1055\/s-0037-1613942","article-title":"Elastase mediated fibrinolysis in acute promyelocytic leukemia","volume":"83","author":"Oudijk","year":"2000","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109746_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117229","article-title":"Neutrophil elastase-mediated proteolysis of the tumor suppressor p200 CUX1 promotes cell proliferation and inhibits cell differentiation in APL","volume":"242","author":"Yu","year":"2020","journal-title":"Life Sci."},{"issue":"13","key":"10.1016\/j.thromres.2026.109746_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133477","article-title":"The coagulopathy of acute promyelocytic leukemia: an updated review of pathophysiology, risk stratification, and clinical management","volume":"15","author":"Hermsen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.thromres.2026.109746_bb0250","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3324\/haematol.2011.044933","article-title":"Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy","volume":"96","author":"B","year":"2011","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.thromres.2026.109746_bb0255","first-page":"1247","article-title":"Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups","volume":"96","author":"Sanz","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2026.109746_bb0260","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.2024026186","article-title":"Acute promyelocytic leukemia: long-term outcomes from the HARMONY project","volume":"145","author":"Voso","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.thromres.2026.109746_bb0265","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1080\/10428194.2020.1742910","article-title":"An effective early death scoring system for predicting early death risk in de novo acute promyelocytic leukemia","volume":"61","author":"Cai","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.thromres.2026.109746_bb0270","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s00277-017-3096-5","article-title":"Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia","volume":"96","author":"Lou","year":"2017","journal-title":"Ann. Hematol."},{"issue":"7","key":"10.1016\/j.thromres.2026.109746_bb0275","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3324\/haematol.2021.280093","article-title":"A risk score based on real-world data to predict early death in acute promyelocytic leukemia","volume":"107","author":"\u00d6sterroos","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.thromres.2026.109746_bb0285","first-page":"795","article-title":"Early death and intracranial hemorrhage prediction in acute promyelocytic leukemia: validation of a risk score in a cohort from an international consortium treated with chemotherapy plus all- trans retinoic acid","volume":"110","author":"Silva","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2026.109746_bb0290","doi-asserted-by":"crossref","DOI":"10.1177\/10760296251360019","article-title":"Establishment and application of warning scoring system for bleeding severity in patients with newly diagnosed acute promyelocytic leukemia","volume":"31","author":"Li","year":"2025","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"23","key":"10.1016\/j.thromres.2026.109746_bb0295","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood.V126.23.3758.3758","article-title":"Coagulopathy in acute promyelocytic leukemia: strategies to improve assessment of hemostatic risk","volume":"126","author":"David","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2026.109746_bb0300","doi-asserted-by":"crossref","DOI":"10.1177\/10760296221119809","article-title":"Application of rotational thromboelastometry in patients with acute Promyelocytic leukemia","volume":"28","author":"Sabljic","year":"2022","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"13","key":"10.1016\/j.thromres.2026.109746_bb0305","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010137","article-title":"The role of thromboelastography in predicting hemorrhage risk in patients with leukemia","volume":"97","author":"Bao","year":"2018","journal-title":"Medicine"},{"issue":"9","key":"10.1016\/j.thromres.2026.109746_bb0310","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.leukres.2013.05.007","article-title":"Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death","volume":"37","author":"Altman","year":"2013","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.thromres.2026.109746_bb0315","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12185-017-2211-7","article-title":"Characteristics features and factors influencing early death in acute promyelocytic leukemia; experience from United Arab Emirates (UAE)","volume":"106","author":"Hassan","year":"2017","journal-title":"Int. J. Hematol."},{"issue":"9","key":"10.1016\/j.thromres.2026.109746_bb0320","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood.V76.9.1704.1704","article-title":"All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. clinical results","volume":"76","author":"Castaigne","year":"1990","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2026.109746_bb0325","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood.V86.3.1072.1072","article-title":"Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid","volume":"86","author":"Falanga","year":"1995","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2026.109746_bb0330","first-page":"156","article-title":"Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid","volume":"8","author":"Falanga","year":"1994","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.thromres.2026.109746_bb0335","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1182\/blood.V84.9.3001.3001","article-title":"All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells","volume":"84","author":"Koyama","year":"1994","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2026.109746_bb0340","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2141.2005.05750.x","article-title":"All-trans retinoic acid-induced downregulation of annexin II expression in myeloid leukaemia cell lines is not confined to acute promyelocytic leukaemia","volume":"131","author":"Olwill","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.thromres.2026.109746_bb0345","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood.V80.9.2176.2176","article-title":"All-Transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases","volume":"80","author":"Fenaux","year":"1992","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.thromres.2026.109746_bb0350","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1538-7836.2004.00787.x","article-title":"Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia","volume":"2","author":"Tallman","year":"2004","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2026.109746_bb0355","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00277-017-2970-5","article-title":"Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1\u03b2","volume":"96","author":"Dunoyer-Geindre","year":"2017","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.thromres.2026.109746_bb0360","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0049-3848(01)00233-X","article-title":"Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia","volume":"102","author":"Zhao","year":"2001","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.thromres.2026.109746_bb0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147545","article-title":"Addition of arsenic trioxide into induction regimens could not accelerate recovery of abnormality of coagulation and fibrinolysis in patients with acute promyelocytic leukemia","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"issue":"36","key":"10.1016\/j.thromres.2026.109746_bb0370","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA traps promote thrombosis","volume":"107","author":"Fuchs","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.thromres.2026.109746_bb0375","article-title":"Extracellular traps increase burden of bleeding by damaging endothelial cell in acute promyelocytic leukaemia","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.thromres.2026.109746_bb0380","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.thromres.2026.109746_bb0385","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","article-title":"Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"113","author":"Sanz","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.thromres.2026.109746_bb0390","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1182\/blood.V108.11.1503.1503","article-title":"Incidence and risk factors for thrombosis in patients with acute promyelocytic leukemia. Experience of the PETHEMA LPA96 and LPA99 protocols","volume":"108","author":"Montesinos","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.thromres.2026.109746_bb0395","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood.V75.11.2112.2112","article-title":"Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients","volume":"75","author":"Rodeghiero","year":"1990","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.thromres.2026.109746_bb0400","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1182\/blood-2017-10-804096","article-title":"How I treat disseminated intravascular coagulation","volume":"131","author":"Levi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2026.109746_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106174","article-title":"Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction","volume":"83","author":"Hambley","year":"2019","journal-title":"Leuk. Res."},{"issue":"11","key":"10.1016\/j.thromres.2026.109746_bb0410","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.leukres.2012.08.012","article-title":"Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation","volume":"36","author":"Ikezoe","year":"2012","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.thromres.2026.109746_bb0415","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.thromres.2014.02.025","article-title":"Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort","volume":"133","author":"Matsushita","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2026.109746_bb0420","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.thromres.2021.04.003","article-title":"Efficacy of recombinant human soluble thrombomodulin in induction therapy for acute promyelocytic leukemia","volume":"202","author":"Matsuda","year":"2021","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.thromres.2026.109746_bb0425","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","article-title":"Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial","volume":"5","author":"Saito","year":"2007","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2026.109746_bb0430","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1600-0609.2004.00237.x","article-title":"Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia","volume":"72","author":"Zver","year":"2004","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.thromres.2026.109746_bb0435","first-page":"410","article-title":"Analysis of clinical efficacy of recombinant activated factor VII on bleeding in patients with hematologic disorders","volume":"38","author":"Liu","year":"2017","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"10.1016\/j.thromres.2026.109746_bb0440","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/10428194.2011.605189","article-title":"Cerebral hemorrhage treated with NovoSeven in acute promyelocytic leukemia","volume":"53","author":"Nosari","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"19","key":"10.1016\/j.thromres.2026.109746_bb0445","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1006221","article-title":"Safety of recombinant activated factor VII in randomized clinical trials","volume":"363","author":"Levi","year":"2010","journal-title":"N. Engl. J. Med."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826001659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826001659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:44:30Z","timestamp":1784133870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384826001659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":87,"alternative-id":["S0049384826001659"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109746","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coagulopathy in acute promyelocytic leukaemia: Can we better predict and prevent catastrophic bleeding?","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109746"}}